TransCode Therapeutics, Inc. - Common Stock (RNAZ)
0.3418
-0.0084 (-2.40%)
NASDAQ · Last Trade: May 10th, 11:08 AM EDT
Detailed Quote
Previous Close
0.3502
Open
0.3600
Bid
0.3317
Ask
0.3410
Day's Range
0.3200 - 0.3600
52 Week Range
0.2196 - 66.33
Volume
1,032,720
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
9,410,956
Chart
About TransCode Therapeutics, Inc. - Common Stock (RNAZ)
Transcode Therapeutics Inc is a biotechnology company focused on developing innovative RNA-based therapeutics aimed at treating cancer and other serious diseases. The company specializes in harnessing the potential of RNA to create targeted therapies that can address the underlying mechanisms of diseases, particularly in oncology. By leveraging its proprietary technology platforms, Transcode aims to enhance the precision of cancer treatments and improve patient outcomes, while also exploring applications in other therapeutic areas. The company's commitment to advancing RNA therapeutics positions it at the forefront of cutting-edge research in the life sciences field. Read More
TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on study, with the longest treated showing stable disease after seven cycles. Early PK/PD data confirm target engagement and support advancing to the Phase 1b dose expansion stage.
TransCode Therapeutics (NASDAQ: RNAZ), the RNA oncology company focused on developing RNA therapeutics to treat cancer, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. Shares will begin trading on a split-adjusted basis that same day under the existing ticker, “RNAZ.” The move, approved by shareholders and the board, aims to raise the company’s per-share price to maintain compliance with Nasdaq’s minimum bid price requirement. Post-split, TransCode’s outstanding common stock will decrease from approximately 23.3 million to about 833,620 shares. No fractional shares will be issued; instead, amounts will be rounded up to the nearest whole share. Vstock Transfer LLC will act as the exchange agent. The new CUSIP number will be 89357L 501.
TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation.
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies— Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ) —each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant. The company secured approximately $10 million in gross proceeds from the offering. TransCode intends to use the proceeds primarily for product development activities, including one or more clinical trials with its lead therapeutic candidate, TTX-MC138, including related IND-enabling studies, as well as for working capital and other general corporate purposes. ThinkEquity acted as sole placement agent for the offering.
